# Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

> **NCT02853929** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 551 (actual)

## Conditions studied

- Diphtheria
- Hepatitis B
- Acellular Pertussis
- Haemophilus Influenzae Type b
- Tetanus
- Poliomyelitis
- Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

## Interventions

- **BIOLOGICAL:** Infanrix hexa

## Key facts

- **NCT ID:** NCT02853929
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-19
- **Primary completion:** 2019-03-19
- **Final completion:** 2019-03-19
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02853929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02853929, "Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02853929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*